CHMP grants Novartis's Afinitor a positive opinion for advanced kidney cancer
This article was originally published in Scrip
Novartis's Afinitor (everolimus) has received an EU CHMP positive opinion for the treatment of advanced renal cell carcinoma in patients whose disease has progressed during or after treatment with VEGF-targeted therapy.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.